Abstract
Introduction
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Metastasis, the spread of cancer cells from an initial tumor site to other areas of the tissue, or to other tissues entirely, is the 11 cause of 90% of cancer-related deaths. Cancer does not metastasize randomly, rather each type of cancer exhibits a tissue-12 specific pattern of spread (called tropism) [3] . Some types, like colon [6] and ovarian cancer [7] , are dictated by circulation 13 patterns and anatomical proximity. But other types of cancer metastasize to distant organs independently of circulation.
2 identify a patient's tumor as invasive [14] [15] [16] [17] . However, biopsies only provide one snapshot of a tumor, with limited ability to 1 predict any stochastic changes in phenotype or mutations that may occur, thus limiting the future efficacy of a patient's drug 2 treatment regimen. Recently, biologists and engineers have sought to understand how the ECM impacts the invasiveness of 3 cancer, and if the ECM itself could be used as a predictive biomarker.
5
Matrix and/or cell stiffness is one such potential predictive marker. Recently a study found that mice with more mechanically 6 compliant primary tumors had more aggressive relapsed tumors at the time of euthanasia [18] . Shear stress due to fluid flow 7 also induces an epithelial to mesenchymal transition (EMT) in ovarian cancer, suggesting that more porous tumors are more 8 metastatic [19] . On in vitro 2D surfaces, Leight et al. found that TGF-1 induced invasion occurs only on rigid surfaces, thereby 9 linking chemical and physical factors on the initiation of EMT [20] . A large study spearheaded by the National Cancer Institute 10 (NCI) recently showed that physical differences (such as cell compliance, traction forces) are enough to distinguish between a 11 malignant (MDA-MB-231) and normal (MCF-10A) cell line [21] . This study required massive efforts across many laboratories, so 12 more sophisticated tools, perhaps those that rely on electrical impedance [22] instead of individual cell analysis, are required for 13 high-throughput application.
15
In addition to stiffness, many ECM proteins have documented roles in augmenting or abrogating metastasis (for review, see 16 [23] ). In fact, Weinberg's Hallmarks of Cancer was recently updated to include the role of the ECM in each step of metastasis 17 [24] . The potential for metastasis and the particular distant tissue site may be associated with an identifying "ECM signature" 18 [25] . For example, using ECM-binding as a predictive marker showed that cancer cell binding to combinations of ECM proteins 19 was sufficient to separate metastatic from non-metastatic cell lines [26] . While these are seminal studies, a consistent predictive 20 biomarker of disease prognosis, such as the structure of the ECM, or perhaps an individual or set of proteins within the ECM, has 21 yet to be developed. This is imperative to translate understanding of the physical relationship between a cell and its ECM to 22 clinical treatment.
23
Where will cancer metastasize?
24
Given what we know about the heterogeneous nature of tropism, how do we predict where a cell will metastasize? Ideally 25 clinicians would be able to predict metastatic location with biomarkers in a tumor biopsy or in a blood draw, or with quick in 26 vitro assays. An ideal in vitro platform would have controlled, decoupled properties, be highly reproducible, and be easily 27 transferrable to different laboratories and clinics. In in vitro models, high invasion, motility, and proliferation are generally 
27
FGF5 aid angiogenesis, and IL11 and OPN are involved with osteolysis and remodeling the bone matrix [10] . Similar studies using 28 lung-tropic human cells have identified up to 54 potential genes in mice, most prominently IL13Rα2, SPARC, ID1, and VCAM1, to 29 4 be involved in breast-to-lung metastasis [13] . These genetic markers have thus far provided the only possible predictive 1 biomarkers in the primary tumor, and could serve as future therapeutic targets in the clinic.
3
To augment these genetic efforts, engineers are creating model systems, from simple-to-complex, to represent these tissue sites.
4
These representations typically focus on healthy cells commonly found in these tissues, ECM protein composition, ECM stiffness, 5 and tissue dimensionality. Hydrogels are popular tissue mimics because they recapitulate 3D tissue structure and physiological 6 water content (Figure 3b ) [29] . Natural hydrogels, such as collagen-based systems, elicit biochemical cues well, but over-7 sequester media proteins and cannot simultaneously recapitulate tissue stiffness and biochemical properties. While synthetic 8 polymers can be independently tuned mechanically and chemically, they can be over-simplified, and more fundamental research 9 on tissue properties is needed to make these models more tissue-specific. To combine the advantages of both, Beck et al. arrive in the skeleton, they too are exposed to these cyclic signals, such as compression, hydrostatic pressure, and fluid shear 12 stress. Tumor formation in the bone is inhibited in both breast and ovarian cancer during mechanical load [46, 47] 
11
Predicting drug response for metastatic patients 12 Ideally, once metastasis risk is assessed, developing patient-specific drug regimes will follow. Anti-metastasis drugs include those targeted 13 at vascularization, growth in certain microenvironments, cell-ECM binding, receptor kinases, and cancer stem cells (Figure 2d-f) Figure 3 : In vitro models of the metastatic niche. a) Common sites of breast cancer metastasis and their published stiffnesses (Young's modulus). These sites consist of tissue-specific cell types that are part of the metastatic niche. b) These tissues can be represented by natural protein fiber gels or synthetic polymer materials. Polymer matrices can be modified to allow for tissue-specific cell-ECM interactions (via integrin binding) by including oligopeptides responsible for the integrin-binding domains of full-length ECM proteins typically found in these tissues. 8 more reductionist approach as well, e.g., ECM stiffness has been reported to be a powerful mediator of drug response for paclitaxel [79] 
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The authors used a simple, quick 2D adhesion and motility phenotyping platform to predict metastatic outcomes using living cells. 
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The authors demonstrated that there is a differential rigidity response to TGF-beta1, where on soft substrates, cells undergo apoptosis, 
